TWOEquity · Weekly research terminal

6661

Welgene Biotech Co.,Ltd.

TW Healthcare Diagnostics & Research

Latest week
14 Aug 2026
Weekly close
16.75 TWD
Fair value
21.88 TWD
Next-week expectancy
Undecided 49.20%
Sharemaestro
Weekly Chart Pack Completed weekly market data · Independent research

TWO · Equity · Taiwan

6661

Welgene Biotech Co.,Ltd.

Healthcare Diagnostics & Research

Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables, and instruments, as well as software services. Welgene Biotech Co.,Ltd. was founded in 2003 and is based in Taipei City, Taiwan.

Last updated
14 Aug 2026
Exchange
Taipei Exchange · TWO
Sector
Healthcare
Industry
Diagnostics & Research
Currency
TWD
Market capitalisation
390,346,144
Fair value reference
21.88
Next-week expectancy
Undecided · 49.20%

Over the latest 12 completed weeks ending 2026-08-14, 6661 fell 1.76%, moving from 17.05 to 16.75. The latest weekly close is below the Trend Line and below Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 12 weeks. Relative Strength is -37.99 and has improved across the 12-week window. Market Dynamics is 0.18 on the latest week. Next-week expectancy is undecided at 49.20% based on similar historical setup states.

Week Ending
14 Aug 2026
Latest Close
16.75
12-Week Change
-1.76%
Trend Signal
Inactive
Next-Week Expectancy
Undecided 49.20%
Signal Weeks
0 of 12

Weekly Price

Weekly Close Trend Line Fair Value Activity Lines

Chart Panels

Choose up to 5 panels. Drag panel headers to reorder.

Chart Summary

Key Points

Week Ending
14 Aug 2026
Latest Close
16.75
12-Week Change
-1.76%
Trend Signal
Inactive
Next-Week Expectancy
Undecided 49.20%
Signal Weeks
0 of 12
Vs Trend Line
Below
Vs Fair Value
Below
Relative Strength
-37.99
Market Dynamics
0.18

Over the latest 12 completed weeks ending 2026-08-14, 6661 fell 1.76%, moving from 17.05 to 16.75. The latest weekly close is below the Trend Line and below Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 12 weeks. Relative Strength is -37.99 and has improved across the 12-week window. Market Dynamics is 0.18 on the latest week. Next-week expectancy is undecided at 49.20% based on similar historical setup states.

Industry Peers

Taiwan equities in Diagnostics & Research

Stock Exchange Week Open High Low Close Change
6847 Puriblood Medical Co., Ltd. TWO 14 Aug 2026 77.70 81.40 75.80 79.30 2.06%
6939 TFBS Bioscience Inc. TWO 14 Aug 2026 19.50 20.00 18.70 19.65 0.77%
7595 Pharmigene, Inc. TWO 14 Aug 2026 7.20 7.36 6.90 7.25 0.69%
1784 BIONET Corp. TWO 14 Aug 2026 60.20 62.90 60.20 60.60 0.66%
4160 Genetics Generation Advancement Corp. TWO 14 Aug 2026 40.15 41.00 39.40 39.80 -0.87%
6615 Sofiva Genomics Co.,Ltd. TWO 14 Aug 2026 34.20 34.60 33.45 33.75 -1.32%
4153 DIVA Laboratories, Ltd. TWO 14 Aug 2026 33.45 33.45 32.40 33.00 -1.35%
6645 Kim Forest Enterprise Co., Ltd. TAI 14 Aug 2026 13.55 13.60 13.10 13.25 -2.21%

Next-week expectancy

Next-week expectancy is a short-term historical read. It compares the latest completed-week setup with broadly similar past setups and asks whether the following week tended to close higher or lower.

It is not a trend call, a price target, or a guarantee. A positive read can appear while price is below trend or activity pressure is weak, because it is measuring short-term follow-through odds for the current setup state.

Use it as one context layer beside Trend Line, Relative Strength, Market Dynamics, Fair Value, and the visible price structure.

Evidence context